^
Association details:
| Biomarker: | MYC amplification |
|---|---|
| Cancer: | Medulloblastoma |
| Drug: | onvansertib (PCM-075) (PLK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy
Published date:
09/03/2021
Excerpt:
Group 3 medulloblastoma (MB) is often accompanied by MYC amplification....Onvansertib reduced colony formation, cell proliferation, stem cell renewal and induced G2/M arrest in vitro....These findings demonstrate the efficacy of a novel PLK1 inhibitor onvansertib in vitro and in xenografts of Group 3 MB
DOI:
10.1093/neuonc/noab207
